Phase 2a study (Part 1) – A phase 2a study to evaluate the safety, pharmacokinetics and clinical activity of the PI3K/mTOR inhibitor GDC-0084 administered to patients with glioblastoma multiforme characterized by unmethylated O6-methylguaninemethyltransferase promoter status. Phase 2b study (Part 2) – A randomized, open-label, multicenter, phase 2b study to assess the efficacy and safety of the PI3K/mTOR inhibitor GDC-0084 compared to temozolomide as adjuvant therapy for the treatment of newly diagnosed glioblastoma multiforme with unmethylated O6-methylguanine-methyltransferase promoter status following surgical resection and standard concomitant chemoradiation therapy with temozolomide

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Novogen

Protocol Number
Kazia (Novogen) NVGN-0084-201

To Learn More Call
(201)-510-0950